Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected. This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects.

Subjects will receive standard treatment for autologous stem cell transplant. Subjects will be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects will receive oral Eltrombopag on days 2-15 of treatment.

Inclusion Criteria:

• Multiple myeloma
• Stable or responsive disease after at least 2 cycles of conventional chemotherapy
• Slated to undergo autologous peripheral blood stem cell transplant
• Normal organ and marrow function

Exclusion Criteria:

• Myocardial infarction within 6 months of treatment
• Receiving other study agents
• Pregnant or breastfeeding
• Uncontrolled intercurrent illness
• Evidence of active or recent history of thromboembolic disease
• Previous history of primary platelet disorder or bleeding disorder
• History of a different malignancy unless disease free for at least 5 years